Results of cholesterol human volunteer study

Results of cholesterol human volunteer study

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol and diabetes, announces that further to its announcement of successful humans studies on its capsular supplement to reduce cholesterol on 28 July 2015, more detail on the results of the study.

The twelve week double blind placebo controlled study recruited fifty volunteers and was designed to establish safety, compliance, and the extent of the cholesterol lowering potential of OptiBiotix’s Lactobacillus plantarum strain in mildly hypercholesterolaemic adults.

When volunteers taking placebo were compared to those taking OptiBiotix’s capsular supplement the results showed a:-

· 7.2% reduction in LDL cholesterol (bad cholesterol) averaged across the whole test group

· 12.4% reduction in LDL cholesterol in females volunteers

· 15% reduction in the 50-55 age groups (both sexes)

· 36.7% reduction in volunteers’ who had total cholesterol levels higher than 6mmol/L

· A 6mmHg (5.1%) reduction in systolic blood pressure averaged across the OptiBiotix group

No safety, compliance, or tolerance issues were reported by volunteers during the study in either group.

The results of this independent, blinded study provide early evidence that OptiBiotix’s strain has commercial potential as a safe, easy to use, low cost, cholesterol reducing supplement. These results suggest efficacy across all volunteers similar or greater to 1.5 – 2.4 g plant sterols/stanols per day, and in volunteers with total cholesterol level greater than 6mmol/L an efficacy more typically associated with pharmaceuticals.

Stephen O’Hara, CEO of OptiBiotix, commented: “We are really pleased with the results of this study which opens up opportunities for a single product for both conditions (high cholesterol and high blood pressure) or two different products targeting separate conditions. Given the market opportunity and limitations of existing products such as statins, the commercial potential for this product looks promising. Commercial discussions are progressing with potential partners best positioned to fully exploit the opportunity as a cholesterol and/or hypertension supplement, in isolation, or in combination with existing approaches.”

Important information

This information is of a general nature and does not constitute an offer to provide services.

The opinions and conclusions given here are those of Seneca Partners and are subject to change without notice.

The value of investments and/or any income arising from them may fluctuate.

Past performance is not necessarily a guide to future performance.

Important notice

The products and services shown on this website place capital at risk. Investors may receive less in returns than they have invested. Investments may not allow for capital to be withdrawn on demand. If an investment provides tax relief then this relief is subject to change and is dependant on personal circumstances. Any reference to past performance or forecasted performance is not a reliable indicator of future performance.

Seneca Partners recommends that any investor seeks specialised financial and/or tax advice before investing. Seneca Partners does not provide advice and the information on this website, including but not limited to news, should not be construed as such.

Please confirm that you understand this warning and wish to proceed.